Histone deacetylases: Structural determinants of inhibitor selectivity

Drug Discovery Today

Volumn 20, Issue 6, 2015, Pages 718-735

  Micelli, Carmina ^a   Rastelli, Giulio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE; CYCLOPROPANE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; KETONE DERIVATIVE; TRIFLUOROMETHYLKETONE; UNCLASSIFIED DRUG; ISOENZYME; LIGAND; PROTEIN BINDING;

ARTICLE; CATALYSIS; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME LOCALIZATION; ENZYME STRUCTURE; HUMAN; METAL BINDING; NONHUMAN; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; ENZYME SPECIFICITY; METABOLISM; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; CATALYTIC DOMAIN; DRUG DESIGN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; ISOENZYMES; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84934980208     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.01.007     Document Type: Review

References (93)

1. Weichert, W. (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 280, 168-176
2. Esteller, M. (2008) Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159
3. Arrowsmith, C. H. et al. (2012) Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400
4. Dekker, F. J. and Haisma, H. J. (2009) Histone acetyl transferases as emerging drug targets. Drug Discov. Today 14, 942-948
5. Yang, X.-J. and Seto, E. (2003) Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr. Opin. Genet. Dev. 13, 143-153
6. Kim, S. C. et al. (2006) Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 23, 607-618
7. Choudhary, C. et al. (2009) Lysine acetylation targets protein complexes and coregulates major cellular functions. Science 325, 834-840
8. Smith, K. T. and Workman, J. L. (2009) Introducing the acetylome. Nat. Biotechnol. 27, 917-919
9. Spange, S. et al. (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 41, 185-198
10. Ververis, K. et al. (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7, 47-60
11. Ocker, M. (2010) Deacetylase inhibitors: focus on non-histone targets and effects. World J. Biol. Chem. 1, 55-61
12. Hui, K. F. and Chiang, A. K. S. (2014) Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism. Int. J. Cancer 135, 2950-2961
13. Shakespear, M. R. et al. (2011) Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 32, 335-343
14. McKinsey, T. A. (2012) Therapeutic potential for HDAC inhibitors in the heart. Annu. Rev. Pharmacol. Toxicol. 52, 303-319
15. Gräff, J. et al. (2011) Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol. Rev. 91, 603-649
16. Wiech, N. L. et al. (2009) Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders. Curr. Top. Med. Chem. 9, 257-271
17. Sjöblom, T. et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274
18. Ropero, S. et al. (2006) A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38, 566-569
19. Decroos, C. et al. (2014) Compromised structure and function of HDAC8 mutants identified in Cornelia de Lange Syndrome spectrum disorders. ACS Chem. Biol. 9, 2157-2164
20. Marks, P. A. et al. (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92, 1210-1216
21. New, M. et al. (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol. Oncol. 6, 637-656
22. Hrabeta, J. et al. (2014) Histone deacetylase inhibitors in cancer therapy. A review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 158, 161-169
23. Li, Z. and Zhu, W.-G. (2014) Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int. J. Biol. Sci. 10, 757-770
24. Bolden, J. E. et al. (2006) Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784
25. West, A. C. and Johnstone, R. W. (2014) New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30-39
26. Marks, P. A. (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26, 1351-1356
27. Whittaker, S. J. et al. (2010) Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28, 4485-4491
28. Khot, A. et al. (2013) Romidepsin for peripheral T-cell lymphoma. Expert Rev. Hematol. 6, 351-359
29. Poole, R. M. (2014) Belinostat: first global approval. Drugs 74, 1543-1554
30. Zhang, L. et al. (2015) Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy. Med. Res. Rev. 35, 63-84
31. Thaler, F. and Mercurio, C. (2014) Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next. ChemMedChem 9, 523-526
32. Miller, C. P. et al. (2011) Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J. Biomed. Biotechnol. 2011, 514261
33. Bernstein, B. E. et al. (2000) Genomewide studies of histone deacetylase function in yeast. Proc. Natl. Acad. Sci. U. S. A. 97, 13708-13713
34. De Ruijter, A. J. M. et al. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737-749
35. Gregoretti, I. V. et al. (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338, 17-31
36. North, B. J. and Verdin, E. (2004) Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 5, 224
37. Butler, K. V. et al. (2010) Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatinA. J. Am. Chem. Soc. 132, 10842-10846
38. Christianson, D. W. et al. (1989) Binding of D-phenylalanine and D-tyrosine to carboxypeptidase A. J. Biol. Chem. 264, 12849-12853
39. Fersht, A. R. and Sperling, J. (1973) The charge relay system in chymotrypsin and chymotrypsinogen. J. Mol. Biol. 74, 137-149
40. Finnin, M. S. et al. (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188-193
41. Vanommeslaeghe, K. et al. (2005) Theoretical study revealing the functioning of a novel combination of catalytic motifs in histone deacetylase. Bioorg. Med. Chem. 13, 3987-3992
42. Corminboeuf, C. et al. (2006) Unexpected deacetylation mechanism suggested by a density functional theory QM/MM study of histone-deacetylase-like protein. J. Am. Chem. Soc. 128, 4530-4531
43. Millard, C. J. et al. (2013) Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol. Cell 51, 57-67
44. Bressi, J. C. et al. (2010) Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N-(2-aminophenyl) benzamides. Bioorg. Med. Chem. Lett. 20, 3142-3145
45. Lauffer, B. E. L. et al. (2013) Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J. Biol. Chem. 288, 26926-26943
46. Watson, P. J. et al. (2012) Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature 481, 335-340
47. Bottomley, M. J. et al. (2008) Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem. 283, 26694-26704
48. Burli, R. W. et al. (2013) Design, synthesis, and biological evaluation of potent and selective class iia histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. J. Med. Chem. 56, 9934-9954
49. Schuetz, A. et al. (2008) Human HDAC7 harbors a class IIa histone deacetylasespecific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 283, 11355-11363
50. Lobera, M. et al. (2013) Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat. Chem. Biol. 9, 319-325
51. Vannini, A. et al. (2007) Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep. 8, 879-884
52. Somoza, J. R. et al. (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12, 1325-1334
53. Vannini, A. et al. (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. U. S. A. 101, 15064-15069
54. Whitehead, L. et al. (2011) Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. Bioorg. Med. Chem. 19, 4626-4634
55. Dowling, D. P. et al. (2010) Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function. Biochemistry 49, 5048-5056
56. Dowling, D. P. et al. (2008) Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Biochemistry 47, 13554-13563
57. Cole, K. E. et al. (2011) Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitorofthe histonedeacetylases. J. Am. Chem. Soc. 133, 12474-12477
58. Schäfer, S. et al. (2008) Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg. Med. Chem. 16, 2011-2033
59. Nielsen, T. K. et al. (2007) Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor. Acta Crystallogr. F 63, 270-273
60. Nielsen, T. K. et al. (2005) Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol. 354, 107-120
61. Kadosh, D. and Struhl, K. (1998) Histone deacetylase activity of Rpd3 is important for transcriptional repression in vivo. Genes Dev. 12, 797-805
62. Hassig, C. A. et al. (1998) A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc. Natl. Acad. Sci. U. S. A. 95, 3519-3524
63. Lahm, A. et al. (2007) Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 104, 17335-17340
64. Gantt, S. L. et al. (2006) Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry 45, 6170-6178
65. Gantt, S. L. et al. (2010) Activation and inhibition of histone deacetylase 8 by monovalent cations. J. Biol. Chem. 285, 6036-6043
66. Chen, K. et al. (2014) Inhibition and mechanism of HDAC8 revisited. J. Am. Chem. Soc. 136, 11636-11643
67. Chou, C. J. et al. (2008) Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem. 283, 35402-35409
68. Estiu, G. et al. (2010) On the inhibition of histone deacetylase 8. Bioorg. Med. Chem. 18, 4103-4110
69. Sixto-López, Y. et al. (2014) Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies. Appl. Biochem. Biotechnol. 173, 1907-1926
70. Estiu, G. et al. (2008) Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem. 51, 2898-2906
71. Weerasinghe, S. V. W. et al. (2008) Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoformselective histone deacetylase inhibitors. J. Med. Chem. 51, 5542-5551
72. Fischle, W. et al. (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45-57
73. Yang, X.-J. and Seto, E. (2008) The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9, 206-218
74. Delcuve, G. P. et al. (2012) Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin. Epigenetics 4, 5
75. Hu, E. et al. (2000) Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J. Biol. Chem. 275, 15254-15264
76. Balasubramanian, S. et al. (2008) A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22, 1026-1034
77. Botta, C. B. et al. (2011) Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation. J. Med. Chem. 54, 2165-2182
78. Summers, J. B. et al. (1987) In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. J. Med. Chem. 30, 2121-2126
79. Mann, B. S. et al. (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res. 13, 2318-2322
80. Wang, D. et al. (2007) Zinc binding in HDAC inhibitors: a DFT study. J. Org. Chem. 72, 5446-5449
81. Vanommeslaeghe, K. et al. (2003) Ab initio study of the binding of Trichostatin A (TSA) in the active site of histone deacetylase like protein (HDLP). Org. Biomol. Chem. 1, 2951-2957
82. Vanommeslaeghe, K. et al. (2005) DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors. Bioorg. Med. Chem. 13, 6070-6082
83. Chen, K. et al. (2013) Computational exploration of zinc binding groups for HDAC inhibition. J. Org. Chem. 78, 5051-5055
84. Khan, N. et al. (2008) Determination of the class and isoform selectivity of smallmolecule histone deacetylase inhibitors. Biochem. J. 409, 581-589
85. Wang, D.-F. et al. (2004) On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J. Med. Chem. 47, 3409-3417
86. Kalyaanamoorthy, S. and Chen, Y.-P. P. (2012) Exploring inhibitor release pathways in histone deacetylases using random acceleration molecular dynamics simulations. J. Chem. Inf. Model. 52, 589-603
87. Wambua, M. K. et al. (2014) Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design. J. Med. Chem. 57, 642-650
88. Hildmann, C. et al. (2006) Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J. Biotechnol. 124, 258-270
89. Lee, H. et al. (2004) Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol. Cell. Biol. 24, 765-773
90. Haider, S. et al. (2011) On the function of the internal cavity of histone deacetylase protein 8:R37 is a crucial residue for catalysis. Bioorg. Med. Chem. Lett. 21, 2129-2132
91. Jones, P. et al. (2008) 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 18, 3456-3461
92. Jones, P. et al. (2008) Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg. Med. Chem. Lett. 18, 1814-1819
93. Muraglia, E. et al. (2008) 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 18, 6083-6087